Roche has announced a 4% rise in sales in 2012 based on the strong performance of its oncology portfolio which featured the launch of Perjeta (pertuzumab), a new drug for breast cancer. The company expects to maintain this sales momentum in 2013. ---Subscribe to MedNous to access this article--- Company News
